Clinical Trials Arena November 15, 2023
GlobalData Healthcare

Chikungunya is a mosquito-borne disease, characterised by fever, severe joint pain, headache, nausea, fatigue, and rash.

Valneva recently announced the approval of IXCHIQ by the FDA, marking the world’s first approved chikungunya vaccine. IXCHIQ is a single-dose, live-attenuated vaccine for use in adults 18 years of age and older, for the prevention of disease caused by the chikungunya virus (CHIKV). IXCHIQ has the potential to mitigate a major public health threat and prevent millions of cases of chikungunya worldwide.

Chikungunya is a mosquito-borne disease, characterised by fever, severe joint pain, headache, nausea, fatigue, and rash, that has been identified in over 110 countries across Asia, Africa, Europe, and the Americas. Despite the significant disease burden, there are currently no treatment...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article